The path of a new drug from the idea to product may be divided into 2 phases, namely drug discovery and drug development.
In drug discovery a dramatic change is taking place.
Due to a remarkable progress in understanding and explaining the underlying cause of many diseases by identifying and sequencing the genes encoded within DNA, it has become possible with new methods, like molecular biology or gene technology, to develop simple test assays by which a large number of compounds may be tested in regard to their biological efficacy.
Automation of these test systems utilizing computer-controlled robotic systems has made it possible to evaluate up to 1 million substances per robot per year on their biological effect.
While the classical medicinal chemistry cannot produce such a large number of new compounds, combinatorial chemistry may offer the opportunity to screen large numbers of novel compounds rapidly and to reduce the time taken to identify drug candidates substantially.
Overall, it is estimated that combinatorial chemistry techniques have resulted in a reduction in the time taken to identify drug candidates of between 18 - 24 months.
In drug development 2 partly overlapping phases can be differentiated, namely the preclinical and clinical phase. (...)
Mots-clés Pascal : Recherche développement, Médicament, Industrie pharmaceutique, Biologie moléculaire, Biotechnologie, Génétique, Chimie combinatoire, Test activité, Essai préclinique, Méthodologie, Essai clinique, Article synthèse, Assistance ordinateur
Mots-clés Pascal anglais : Research and development, Drug, Pharmaceutical industry, Molecular biology, Biotechnology, Genetics, Combinatorial chemistry, Screening test, Preclinical trial, Methodology, Clinical trial, Review, Computer aid
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0080613
Code Inist : 002B30A08. Création : 14/05/1998.